Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 59Small Cell Lung Carcinoma 13Lung Neoplasms 13Colorectal Neoplasms 6Sarcoma 5Neoplasm Metastasis 5Melanoma 5Adenocarcinoma of Lung 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3NSCLC 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Mesothelioma 2Extensive Stage Small Cell Lung Cancer 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Uveal Melanoma 1Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Germ Cell Tumor 1Small Cell Lung Cancer Extensive Stage 1SCLC, Extensive Stage 1Radiation Pneumonitis 1Perioperative Immunotherapy 1Pancreatic Neoplasms 1Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder) 1Non Squamous Non-small Cell Lung Cancer 1

Interventions

toripalimab 1tislelizumab 1sintilimab 1pembrolizumab 1durvalumab 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
High-Risk Resectable NSCLC × tislelizumab × Thoracic × Clear all
NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 1 Completed
27 enrolled
Thoracic

High-Risk Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡